159 related articles for article (PubMed ID: 27430370)
1. Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
Watson HA; Dolton G; Ohme J; Ladell K; Vigar M; Wehenkel S; Hindley J; Mohammed RN; Miners K; Luckwell RA; Price DA; Matthews RJ; Ager A
Immunol Cell Biol; 2016 Sep; 94(8):802-8. PubMed ID: 27430370
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
[TBL] [Abstract][Full Text] [Related]
3. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
Stromnes IM; Fowler C; Casamina CC; Georgopolos CM; McAfee MS; Schmitt TM; Tan X; Kim TD; Choi I; Blattman JN; Greenberg PD
J Immunol; 2012 Aug; 189(4):1812-25. PubMed ID: 22798667
[TBL] [Abstract][Full Text] [Related]
5. SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
Hebeisen M; Baitsch L; Presotto D; Baumgaertner P; Romero P; Michielin O; Speiser DE; Rufer N
J Clin Invest; 2013 Mar; 123(3):1044-56. PubMed ID: 23391724
[TBL] [Abstract][Full Text] [Related]
6. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
Fowler CC; Pao LI; Blattman JN; Greenberg PD
J Immunol; 2010 Sep; 185(6):3256-67. PubMed ID: 20696858
[TBL] [Abstract][Full Text] [Related]
7. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
8. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
10. Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Ng SSM; Nagy BA; Jensen SM; Hu X; Alicea C; Fox BA; Felber BK; Bergamaschi C; Pavlakis GN
Clin Cancer Res; 2017 Jun; 23(11):2817-2830. PubMed ID: 27986749
[No Abstract] [Full Text] [Related]
11. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
[TBL] [Abstract][Full Text] [Related]
12. SHP-1: the next checkpoint target for cancer immunotherapy?
Watson HA; Wehenkel S; Matthews J; Ager A
Biochem Soc Trans; 2016 Apr; 44(2):356-62. PubMed ID: 27068940
[TBL] [Abstract][Full Text] [Related]
13. Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function.
Sathish JG; Dolton G; Leroy FG; Matthews RJ
J Immunol; 2007 Jan; 178(1):330-7. PubMed ID: 17182570
[TBL] [Abstract][Full Text] [Related]
14. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
15. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
16. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
17. Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
Luo Q; Sun Y; Gong FY; Liu W; Zheng W; Shen Y; Hua ZC; Xu Q
Br J Pharmacol; 2014 Apr; 171(7):1706-21. PubMed ID: 24372081
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
